AstraZeneca disinvest hypertension medicines to Atnahs Pharma

AstraZeneca divest its global commercial rights of Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) Atnahs Pharma.

Under the terms of the agreement, AstraZeneca has received a payment of US$ 350 million from Atnahs. The company may also receive future sales-contingent payments of up to US$ 40 million between 2020 and 2022. The upfront payment will be reported in AstraZeneca’s financial statements within Other Operating Income & Expense in the first quarter of 2020.

• Inderal (propranolol) is a beta-blocker and is predominantly used to treat tremors, angina, hypertension, arrhythmias, and other heart or circulatory conditions. It is also used to reduce the severity and frequency of migraine.
• Tenormin (atenolol) is a beta-blocker that is used to treat angina and hypertension, as well as certain kinds of arrhythmias. It is also used to lower the risk of death after a heart attack. Tenoretic is a fixed-dose combination of atenolol (beta-blocker) and chlorthalidone (diuretic), used to treat high blood pressure.
• Zestril (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension, congestive heart failure, diabetic-related conditions and hypertensive renal disease. Zestril may also be used to improve survival after a heart attack.
• Zestoretic is a fixed-dose combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (diuretic) used to treat hypertension.